Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Contraception ; 90(2): 142-6, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24813941

RESUMEN

OBJECTIVE: To examine the impact of subject characteristics on efficacy as measured by the Pearl Index (PI) in clinical trials and to make study populations similar by matching. METHODS: Our analysis used US data from four large Phase III studies. We compared results from one fertility control patch study with pooled data from three studies with virtually identical design on oral hormonal contraceptives. First, we identified three characteristics that had the most impact on the PI. Second, we used these three variables and matched subjects from the patch study with those from the oral contraceptive (OC) studies. Finally, we calculated the PIs for matched and unmatched subjects from both the patch study and the OC studies. RESULTS: A total of 3706 subjects were included in our analysis. The variables 'Hispanic ethnicity', 'previous pregnancy' and 'previous use of hormonal contraceptives' had the most impact on the PI. The PIs for the matched patch cohort and the matched OC cohort were 2.97 and 2.48, respectively. Those for the unmatched patch cohort and the unmatched OC cohort were 10.17 and 0.90, respectively. CONCLUSION: Subject characteristics strongly influence the PI in clinical studies of hormonal contraceptives. In particular, Hispanic ethnicity, previous pregnancies and no previous use of hormonal contraceptives result in a higher PI. IMPLICATIONS: PIs from different clinical trials cannot be meaningfully compared unless subject characteristics that have most impact on the PI are similar or are made to be similar statistically as we did here by matching.


Asunto(s)
Anticonceptivos Femeninos/administración & dosificación , Progestinas/administración & dosificación , Adulto , Androstenos/administración & dosificación , Androstenos/efectos adversos , Estudios de Cohortes , Anticonceptivos Femeninos/efectos adversos , Anticonceptivos Hormonales Orales/administración & dosificación , Anticonceptivos Hormonales Orales/efectos adversos , Estradiol/administración & dosificación , Estradiol/efectos adversos , Estradiol/análogos & derivados , Etinilestradiol/administración & dosificación , Etinilestradiol/efectos adversos , Europa (Continente) , Femenino , Humanos , Análisis de Intención de Tratar , Análisis por Apareamiento , Nandrolona/administración & dosificación , Nandrolona/efectos adversos , Nandrolona/análogos & derivados , Norpregnenos/administración & dosificación , Norpregnenos/efectos adversos , Embarazo , Embarazo no Deseado , Progestinas/efectos adversos , Medición de Riesgo , América del Sur , Parche Transdérmico/efectos adversos , Estados Unidos , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA